These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
(Mark One)
|
|
|
|
|
|
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
|
Large Accelerated Filer
þ
|
|
Accelerated Filer
o
|
|
Non-Accelerated Filer
o
|
|
Smaller Reporting Company
o
|
|
(Do not check if a smaller reporting company.)
|
Emerging Growth Company
o
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions except per share data - unaudited)
|
2017
|
|
|
2016
|
|
||
Sales
|
$
|
842
|
|
|
$
|
704
|
|
Cost of sales
|
613
|
|
|
515
|
|
||
Gross profit
|
229
|
|
|
189
|
|
||
|
|
|
|
||||
Selling, general and administrative expense
|
171
|
|
|
157
|
|
||
Research and development expense
|
21
|
|
|
20
|
|
||
Equity and other income
|
2
|
|
|
3
|
|
||
Operating income
|
39
|
|
|
15
|
|
||
|
|
|
|
||||
Net interest and other financing expense
|
31
|
|
|
122
|
|
||
Other net periodic benefit income
|
—
|
|
|
2
|
|
||
Net loss on divestitures
|
1
|
|
|
1
|
|
||
Income (loss) from continuing operations before income taxes
|
7
|
|
|
(106
|
)
|
||
Income tax expense (benefit) - Note I
|
14
|
|
|
(41
|
)
|
||
Loss from continuing operations
|
(7
|
)
|
|
(65
|
)
|
||
Income from discontinued operations (net of tax) - Note D
|
3
|
|
|
75
|
|
||
Net income (loss)
|
(4
|
)
|
|
10
|
|
||
Net income attributable to noncontrolling interest
(a)
|
—
|
|
|
11
|
|
||
Net loss attributable to Ashland
|
$
|
(4
|
)
|
|
$
|
(1
|
)
|
|
|
|
|
||||
PER SHARE DATA
|
|
|
|
||||
Basic earnings per share - Note L
|
|
|
|
|
|
||
Loss from continuing operations
|
$
|
(0.12
|
)
|
|
$
|
(1.05
|
)
|
Income from discontinued operations attributable to Ashland
|
0.05
|
|
|
1.04
|
|
||
Net loss attributable to Ashland
|
$
|
(0.07
|
)
|
|
$
|
(0.01
|
)
|
|
|
|
|
||||
Diluted earnings per share - Note L
|
|
|
|
|
|
||
Loss from continuing operations
|
$
|
(0.12
|
)
|
|
$
|
(1.05
|
)
|
Income from discontinued operations attributable to Ashland
|
0.05
|
|
|
1.04
|
|
||
Net loss attributable to Ashland
|
$
|
(0.07
|
)
|
|
$
|
(0.01
|
)
|
|
|
|
|
||||
COMPREHENSIVE INCOME (LOSS)
|
|
|
|
||||
Net income (loss)
|
$
|
(4
|
)
|
|
$
|
10
|
|
Other comprehensive income (loss), net of tax - Note M
|
|
|
|
||||
Unrealized translation gain (loss)
|
3
|
|
|
(146
|
)
|
||
Net change in available-for-sale securities
|
8
|
|
|
—
|
|
||
Pension and postretirement obligation adjustment
|
—
|
|
|
(1
|
)
|
||
Other comprehensive income (loss)
|
11
|
|
|
(147
|
)
|
||
Comprehensive income (loss)
|
$
|
7
|
|
|
$
|
(137
|
)
|
Comprehensive income attributable to noncontrolling interest
|
—
|
|
|
10
|
|
||
Comprehensive income (loss) attributable to Ashland
|
$
|
7
|
|
|
$
|
(147
|
)
|
|
|
|
|
(a)
|
For the three months ended December 31, 2016, this represents the income attributable to the previous noncontrolling interest in Valvoline Inc., whose results are now included within discontinued operations. See Note B for more information.
|
|
|
|
|
|
|
|
|
|
|
December 31
|
|
|
September 30
|
|
||
(In millions - unaudited)
|
2017
|
|
|
2017
|
|
||
|
|
|
|
||||
ASSETS
|
|
|
|
||||
Current assets
|
|
|
|
||||
Cash and cash equivalents
|
$
|
601
|
|
|
$
|
566
|
|
Accounts receivable
(a)
|
597
|
|
|
612
|
|
||
Inventories - Note F
|
674
|
|
|
634
|
|
||
Other assets
|
92
|
|
|
91
|
|
||
Total current assets
|
1,964
|
|
|
1,903
|
|
||
Noncurrent assets
|
|
|
|
|
|
||
Property, plant and equipment
|
|
|
|
||||
Cost
|
3,795
|
|
|
3,762
|
|
||
Accumulated depreciation
|
1,850
|
|
|
1,792
|
|
||
Net property, plant and equipment
|
1,945
|
|
|
1,970
|
|
||
Goodwill - Note G
|
2,475
|
|
|
2,465
|
|
||
Intangibles - Note G
|
1,298
|
|
|
1,319
|
|
||
Restricted investments - Note E
|
315
|
|
|
302
|
|
||
Asbestos insurance receivable - Note K
|
205
|
|
|
209
|
|
||
Deferred and other income taxes
|
28
|
|
|
28
|
|
||
Other assets
|
425
|
|
|
422
|
|
||
Total noncurrent assets
|
6,691
|
|
|
6,715
|
|
||
Total assets
|
$
|
8,655
|
|
|
$
|
8,618
|
|
|
|
|
|
||||
LIABILITIES AND EQUITY
|
|
|
|
|
|
||
Current liabilities
|
|
|
|
|
|
||
Short-term debt - Note H
|
$
|
355
|
|
|
$
|
235
|
|
Trade and other payables
|
382
|
|
|
409
|
|
||
Accrued expenses and other liabilities
|
266
|
|
|
324
|
|
||
Total current liabilities
|
1,003
|
|
|
968
|
|
||
Noncurrent liabilities
|
|
|
|
|
|
||
Long-term debt - Note H
|
2,584
|
|
|
2,584
|
|
||
Asbestos litigation reserve - Note K
|
676
|
|
|
694
|
|
||
Deferred and other income taxes
|
390
|
|
|
375
|
|
||
Employee benefit obligations - Note J
|
194
|
|
|
191
|
|
||
Other liabilities
|
409
|
|
|
400
|
|
||
Total noncurrent liabilities
|
4,253
|
|
|
4,244
|
|
||
Commitments and contingencies - Note K
|
|
|
|
|
|
||
Stockholders' equity
|
3,399
|
|
|
3,406
|
|
||
|
|
|
|
||||
Total liabilities and stockholders' equity
|
$
|
8,655
|
|
|
$
|
8,618
|
|
|
|
|
|
(a)
|
Accounts receivable includes an allowance for doubtful accounts of
$9 million
at
December 31, 2017
and
September 30, 2017
.
|
|
|
|
|
|
|
|
|
|
(In millions - unaudited)
|
Common
stock
|
|
|
Paid-in
capital
|
|
|
Retained
earnings
|
|
|
Accumulated
other
comprehensive
income (loss)
|
|
(a)
|
Total
|
|
|||||
BALANCE AT SEPTEMBER 30, 2017
|
$
|
1
|
|
|
$
|
931
|
|
|
$
|
2,696
|
|
|
$
|
(222
|
)
|
|
$
|
3,406
|
|
Total comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
||||||||||
Net loss
|
|
|
|
|
|
(4
|
)
|
|
|
|
(4
|
)
|
|||||||
Other comprehensive income
|
|
|
|
|
|
|
11
|
|
|
11
|
|
||||||||
Regular dividends, $0.225 per common share
|
|
|
|
|
|
|
(14
|
)
|
|
|
|
|
(14
|
)
|
|||||
Common shares issued under stock incentive and other plans
(b)
|
|
|
|
—
|
|
|
|
|
|
|
|
—
|
|
||||||
BALANCE AT DECEMBER 31, 2017
|
$
|
1
|
|
|
$
|
931
|
|
|
$
|
2,678
|
|
|
$
|
(211
|
)
|
|
$
|
3,399
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
At
December 31, 2017
and
September 30, 2017
, the after-tax accumulated other comprehensive loss attributable to Ashland of
$211 million
and
$222 million
, respectively, was comprised of net unrealized translation losses of
$243 million
and
$246 million
, respectively, net unrealized gains on available-for-sale securities of
$29 million
and
$21 million
, respectively, and unrecognized prior service credits as a result of certain employee benefit plan amendments of
$3 million
for each period.
|
(b)
|
Common shares issued were
111,400
for the
three
months ended
December 31, 2017
.
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions - unaudited)
|
2017
|
|
|
2016
|
|
||
CASH FLOWS PROVIDED (USED) BY OPERATING ACTIVITIES FROM
|
|
|
|
||||
CONTINUING OPERATIONS
|
|
|
|
||||
Net income (loss)
|
$
|
(4
|
)
|
|
$
|
10
|
|
Income from discontinued operations (net of tax)
|
(3
|
)
|
|
(75
|
)
|
||
Adjustments to reconcile income from continuing operations to
|
|
|
|
|
|
||
cash flows from operating activities
|
|
|
|
|
|
||
Depreciation and amortization
|
79
|
|
|
68
|
|
||
Original issue discount and debt issuance cost amortization
|
2
|
|
|
94
|
|
||
Deferred and other income taxes
|
8
|
|
|
2
|
|
||
Stock based compensation expense
|
7
|
|
|
5
|
|
||
Gain on early retirement of debt
|
—
|
|
|
(3
|
)
|
||
Realized gain and investment income on available-for-sale securities
|
(3
|
)
|
|
(3
|
)
|
||
Net loss on divestitures
|
1
|
|
|
1
|
|
||
Pension contributions
|
(2
|
)
|
|
(1
|
)
|
||
Gain on post-employment plan remeasurement
|
—
|
|
|
(2
|
)
|
||
Change in operating assets and liabilities
(a)
|
(109
|
)
|
|
(156
|
)
|
||
Total cash flows used by operating activities from continuing operations
|
(24
|
)
|
|
(60
|
)
|
||
CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES FROM
|
|
|
|
|
|
||
CONTINUING OPERATIONS
|
|
|
|
|
|
||
Additions to property, plant and equipment
|
(24
|
)
|
|
(33
|
)
|
||
Proceeds from disposal of property, plant and equipment
|
1
|
|
|
—
|
|
||
Proceeds from sale of operations
|
1
|
|
|
—
|
|
||
Net purchase of funds restricted for specific transactions
|
(5
|
)
|
|
(2
|
)
|
||
Reimbursements from restricted investments
|
5
|
|
|
—
|
|
||
Proceeds from sales of available-for-sale securities
|
5
|
|
|
—
|
|
||
Purchases of available-for-sale securities
|
(5
|
)
|
|
—
|
|
||
Proceeds from the settlement of derivative instruments
|
—
|
|
|
4
|
|
||
Payments for the settlement of derivative instruments
|
(2
|
)
|
|
—
|
|
||
Total cash flows used by investing activities from continuing operations
|
(24
|
)
|
|
(31
|
)
|
||
CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES FROM
|
|
|
|
|
|
||
CONTINUING OPERATIONS
|
|
|
|
|
|
||
Repayment of long-term debt
|
(2
|
)
|
|
(239
|
)
|
||
Premium on long-term debt repayment
|
—
|
|
|
(5
|
)
|
||
Proceeds (repayment) from short-term debt
|
120
|
|
|
(154
|
)
|
||
Debt issuance costs
|
—
|
|
|
(4
|
)
|
||
Cash dividends paid
|
(14
|
)
|
|
(24
|
)
|
||
Stock based compensation employee withholding taxes paid in cash
|
(5
|
)
|
|
(8
|
)
|
||
Total cash flows provided (used) by financing activities from continuing operations
|
99
|
|
|
(434
|
)
|
||
CASH USED BY CONTINUING OPERATIONS
|
51
|
|
|
(525
|
)
|
||
Cash provided (used) by discontinued operations
|
|
|
|
|
|
||
Operating cash flows, net
|
(16
|
)
|
|
70
|
|
||
Investing cash flows, net
|
—
|
|
|
(10
|
)
|
||
Financing cash flows, net
|
—
|
|
|
(10
|
)
|
||
Total cash provided (used) by discontinued operations
|
(16
|
)
|
|
50
|
|
||
Effect of currency exchange rate changes on cash and cash equivalents
|
—
|
|
|
(9
|
)
|
||
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
|
35
|
|
|
(484
|
)
|
||
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD
|
566
|
|
|
1,017
|
|
||
Change in cash and cash equivalents held by Valvoline
|
—
|
|
|
(65
|
)
|
||
CASH AND CASH EQUIVALENTS - END OF PERIOD
|
$
|
601
|
|
|
$
|
468
|
|
|
|
|
|
(a)
|
Excludes changes resulting from operations acquired or sold.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
May 12
|
|
|
(In millions)
|
2017
|
|
|
ASSETS
|
|
||
Current assets
|
|
||
Cash
|
179
|
|
|
Accounts receivable, net
|
385
|
|
|
Inventories
|
153
|
|
|
Other current assets
|
24
|
|
|
Total current assets
|
741
|
|
|
Noncurrent assets
|
|
||
Net property, plant and equipment
|
357
|
|
|
Goodwill
|
329
|
|
|
Equity and other unconsolidated investments
|
31
|
|
|
Deferred income taxes
|
391
|
|
|
Other noncurrent assets
|
93
|
|
|
Total noncurrent assets
|
1,201
|
|
|
Total assets
|
$
|
1,942
|
|
LIABILITIES AND EQUITY
|
|
||
Current liabilities
|
|
||
Short-term debt
|
75
|
|
|
Current portion of long-term debt
|
16
|
|
|
Trade and other payables
|
353
|
|
|
Other current liabilities
|
34
|
|
|
Total current liabilities
|
478
|
|
|
Noncurrent liabilities
|
|
||
Long-term debt
|
662
|
|
|
Employee benefit obligations
|
826
|
|
|
Other long-term liabilities
|
163
|
|
|
Total noncurrent liabilities
|
1,651
|
|
|
Total liabilities
|
$
|
2,129
|
|
Net deficit
|
$
|
(187
|
)
|
|
|
|
|
At
|
|
|
|
May 17, 2017
|
|
|
Preliminary purchase price allocation (in millions)
|
As Adjusted
|
|
|
Assets:
|
|
||
Accounts receivable
|
52
|
|
|
Inventory
|
74
|
|
|
Other current assets
|
4
|
|
|
Intangible assets
|
330
|
|
|
Goodwill
|
287
|
|
|
Property, plant and equipment
|
97
|
|
|
Other noncurrent assets
|
20
|
|
|
Liabilities:
|
|
|
|
Accounts payable
|
(32
|
)
|
|
Deferred tax - net
|
(138
|
)
|
|
Other noncurrent liabilities
|
(14
|
)
|
|
Total purchase price
|
$
|
680
|
|
|
|
|
|
|
|
Weighted-average
|
||
|
|
|
amortization period
|
||
Intangible asset type (in millions)
|
Value
|
|
|
(years)
|
|
Trademarks and trade names
|
$
|
26
|
|
|
15
|
Intellectual property
|
68
|
|
|
22
|
|
Customer and supplier relationships
|
236
|
|
|
20
|
|
Total
|
$
|
330
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Income from discontinued operations (net of tax)
|
|
|
|
||||
Valvoline
|
$
|
3
|
|
|
$
|
75
|
|
Total income from discontinued operations (net of tax)
|
$
|
3
|
|
|
$
|
75
|
|
|
Three months ended
|
|
|
(In millions)
|
December 31, 2016
|
|
|
Income from discontinued operations
|
|
||
attributable to Valvoline
|
|
||
Sales
|
$
|
489
|
|
Cost of sales
|
(293
|
)
|
|
Selling, general and administrative expense
|
(82
|
)
|
|
Research and development expense
|
(3
|
)
|
|
Equity and other income
|
9
|
|
|
Operating income of discontinued operations
|
120
|
|
|
Net interest and other financing expense
|
(10
|
)
|
|
Pretax income of discontinued operations
|
110
|
|
|
Income tax expense
|
(35
|
)
|
|
Income from discontinued operations
|
$
|
75
|
|
|
|
|
|
|
|
|
|
|
(In millions)
|
Carrying
value
|
|
|
Total
fair
value
|
|
|
Quoted prices
in active
markets for
identical
assets
Level 1
|
|
|
Significant
other
observable
inputs
Level 2
|
|
|
Significant
unobservable
inputs
Level 3
|
|
|||||
Assets
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash and cash equivalents
|
$
|
601
|
|
|
$
|
601
|
|
|
$
|
601
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Restricted investments
(a)
|
345
|
|
|
345
|
|
|
345
|
|
|
—
|
|
|
—
|
|
|||||
Deferred compensation investments
(b)
|
160
|
|
|
160
|
|
|
—
|
|
|
160
|
|
|
—
|
|
|||||
Investments of captive insurance company
(b)
|
3
|
|
|
3
|
|
|
3
|
|
|
—
|
|
|
—
|
|
|||||
Foreign currency derivatives
|
4
|
|
|
4
|
|
|
—
|
|
|
4
|
|
|
—
|
|
|||||
Total assets at fair value
|
$
|
1,113
|
|
|
$
|
1,113
|
|
|
$
|
949
|
|
|
$
|
164
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Foreign currency derivatives
|
$
|
13
|
|
|
$
|
13
|
|
|
$
|
—
|
|
|
$
|
13
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
Included in restricted investments is
$30 million
classified in the other current assets caption on the Condensed Consolidated Balance Sheets.
|
(b)
|
Included in other noncurrent assets in the Condensed Consolidated Balance Sheets.
|
|
|
|
|
|
|
|
|
|
(In millions)
|
Carrying
value
|
|
|
Total
fair
value
|
|
|
Quoted prices
in active
markets for
identical
assets
Level 1
|
|
|
Significant
other
observable
inputs
Level 2
|
|
|
Significant
unobservable
inputs
Level 3
|
|
|||||
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Cash and cash equivalents
|
$
|
566
|
|
|
$
|
566
|
|
|
$
|
566
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Restricted investments
(a)
|
332
|
|
|
332
|
|
|
332
|
|
|
—
|
|
|
—
|
|
|||||
Deferred compensation investments
(b)
|
158
|
|
|
158
|
|
|
—
|
|
|
158
|
|
|
—
|
|
|||||
Investments of captive insurance company
(b)
|
3
|
|
|
3
|
|
|
3
|
|
|
—
|
|
|
—
|
|
|||||
Foreign currency derivatives
|
2
|
|
|
2
|
|
|
—
|
|
|
2
|
|
|
—
|
|
|||||
Total assets at fair value
|
$
|
1,061
|
|
|
$
|
1,061
|
|
|
$
|
901
|
|
|
$
|
160
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Foreign currency derivatives
|
$
|
36
|
|
|
$
|
36
|
|
|
$
|
—
|
|
|
$
|
36
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
Included in restricted investments is
$30 million
classified in the other current assets caption on the Condensed Consolidated Balance Sheets.
|
(b)
|
Included in other noncurrent assets in the Condensed Consolidated Balance Sheets.
|
|
|
|
|
|
|
|
|
|
|
December 31
|
|
|
September 30
|
|
||
(In millions)
|
2017
|
|
|
2017
|
|
||
Original cost
|
$
|
335
|
|
|
$
|
335
|
|
Accumulated adjustments, net
(a)
|
(38
|
)
|
|
(24
|
)
|
||
Adjusted cost, beginning of year
|
297
|
|
|
311
|
|
||
Investment income
(b)
|
2
|
|
|
9
|
|
||
Unrealized gain
|
45
|
|
|
35
|
|
||
Realized gain
|
1
|
|
|
2
|
|
||
Settlement funds
|
5
|
|
|
2
|
|
||
Disbursements
|
(5
|
)
|
|
(27
|
)
|
||
Fair value
|
$
|
345
|
|
|
$
|
332
|
|
|
|
|
|
(a)
|
The accumulated adjustments include investment income, realized gains, disbursements and settlements recorded in previous periods.
|
(b)
|
Investment income for the demand deposit includes interest income as well as dividend income transferred from the equity and corporate bond mutual funds.
|
|
|
|
Gross
|
|
|
Gross
|
|
|
|
||||||
(In millions)
|
Adjusted Cost
|
|
|
Unrealized Gain
|
|
|
Unrealized Loss
|
|
|
Fair Value
|
|
||||
As of December 31, 2017
|
|
|
|
|
|
|
|
||||||||
Demand Deposit
|
$
|
17
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
17
|
|
Equity Mutual Fund
|
163
|
|
|
45
|
|
|
—
|
|
|
208
|
|
||||
Corporate bond Mutual Fund
|
120
|
|
|
—
|
|
|
—
|
|
|
120
|
|
||||
Fair value
|
$
|
300
|
|
|
$
|
45
|
|
|
$
|
—
|
|
|
$
|
345
|
|
|
|
|
|
|
|
|
|
||||||||
As of September 30, 2017
|
|
|
|
|
|
|
|
||||||||
Demand Deposit
|
$
|
9
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
9
|
|
Equity Mutual Fund
|
168
|
|
|
34
|
|
|
—
|
|
|
202
|
|
||||
Corporate bond Mutual Fund
|
120
|
|
|
1
|
|
|
—
|
|
|
121
|
|
||||
Fair value
|
$
|
297
|
|
|
$
|
35
|
|
|
$
|
—
|
|
|
$
|
332
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Investment income
|
$
|
2
|
|
|
$
|
3
|
|
Realized gains
|
1
|
|
|
—
|
|
||
Disbursements
|
(5
|
)
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Foreign currency derivative loss
|
$
|
(11
|
)
|
|
$
|
(8
|
)
|
|
December 31
|
|
|
September 30
|
|
||
(In millions)
|
2017
|
|
|
2017
|
|
||
Foreign currency derivative assets
|
$
|
4
|
|
|
$
|
2
|
|
Notional contract values
|
425
|
|
|
79
|
|
||
|
|
|
|
||||
Foreign currency derivative liabilities
|
$
|
13
|
|
|
$
|
36
|
|
Notional contract values
|
810
|
|
|
1,601
|
|
|
|
|
|
December 31
|
|
|
September 30
|
|
||
(In millions)
|
2017
|
|
|
2017
|
|
||
Finished products
|
$
|
421
|
|
|
$
|
390
|
|
Raw materials, supplies and work in process
|
256
|
|
|
245
|
|
||
LIFO reserves
|
(3
|
)
|
|
(1
|
)
|
||
|
$
|
674
|
|
|
$
|
634
|
|
|
Specialty
|
|
|
|
|
Intermediates
|
|
|
|
|
|||||
(In millions)
|
Ingredients
|
|
|
Composites
|
|
|
and Solvents
|
|
(a)
|
Total
|
|
||||
Balance as of September 30, 2017
|
$
|
2,315
|
|
|
$
|
150
|
|
|
$
|
—
|
|
|
$
|
2,465
|
|
Currency translation adjustment
|
10
|
|
|
—
|
|
|
—
|
|
|
10
|
|
||||
Balance as of December 31, 2017
|
$
|
2,325
|
|
|
$
|
150
|
|
|
$
|
—
|
|
|
$
|
2,475
|
|
|
|
|
|
|
|
|
|
(a)
|
As of
December 31, 2017
, there was accumulated impairment of
$171 million
related to the Intermediates and Solvents reportable segment.
|
|
|
|
|
|
|
|
|
|
|
December 31, 2017
|
||||||||||
|
Gross
|
|
|
|
|
Net
|
|
||||
|
carrying
|
|
|
Accumulated
|
|
|
carrying
|
|
|||
(In millions)
|
amount
|
|
|
amortization
|
|
|
amount
|
|
|||
Definite-lived intangible assets
|
|
|
|
|
|
||||||
Trademarks and trade names
|
$
|
67
|
|
|
$
|
(22
|
)
|
|
$
|
45
|
|
Intellectual property
|
758
|
|
|
(340
|
)
|
|
418
|
|
|||
Customer and supplier relationships
|
780
|
|
|
(246
|
)
|
|
534
|
|
|||
Total definite-lived intangible assets
|
1,605
|
|
|
(608
|
)
|
|
997
|
|
|||
|
|
|
|
|
|
||||||
Indefinite-lived intangible assets
|
|
|
|
|
|
||||||
Trademarks and trade names
|
301
|
|
|
—
|
|
|
301
|
|
|||
Total intangible assets
|
$
|
1,906
|
|
|
$
|
(608
|
)
|
|
$
|
1,298
|
|
|
September 30, 2017
|
||||||||||
|
Gross
|
|
|
|
|
Net
|
|
||||
|
carrying
|
|
|
Accumulated
|
|
|
carrying
|
|
|||
(In millions)
|
amount
|
|
|
amortization
|
|
|
amount
|
|
|||
Definite-lived intangible assets
|
|
|
|
|
|
||||||
Trademarks and trade names
|
$
|
67
|
|
|
$
|
(22
|
)
|
|
$
|
45
|
|
Intellectual property
|
757
|
|
|
(326
|
)
|
|
431
|
|
|||
Customer and supplier relationships
|
777
|
|
|
(235
|
)
|
|
542
|
|
|||
Total definite-lived intangible assets
|
1,601
|
|
|
(583
|
)
|
|
1,018
|
|
|||
|
|
|
|
|
|
||||||
Indefinite-lived intangible assets
|
|
|
|
|
|
||||||
Trademarks and trade names
|
301
|
|
|
—
|
|
|
301
|
|
|||
Total intangible assets
|
$
|
1,902
|
|
|
$
|
(583
|
)
|
|
$
|
1,319
|
|
|
|
|
|
|
|
|
|
|
|
December 31
|
|
|
September 30
|
|
||
(In millions)
|
2017
|
|
|
2017
|
|
||
4.750% notes, due 2022
|
$
|
1,082
|
|
|
$
|
1,082
|
|
Term Loan B, due 2024
|
597
|
|
|
599
|
|
||
6.875% notes, due 2043
|
376
|
|
|
376
|
|
||
Revolving Credit Facility
|
285
|
|
|
173
|
|
||
Term Loan A, due 2022
|
250
|
|
|
250
|
|
||
Term Loan A, due 2020
|
250
|
|
|
250
|
|
||
Accounts receivable securitization
|
64
|
|
|
56
|
|
||
6.50% junior subordinated notes, due 2029
|
51
|
|
|
51
|
|
||
Medium-term notes, due 2019, interest of 9.4% at December 31, 2017
|
5
|
|
|
5
|
|
||
Other
(a)
|
(21
|
)
|
|
(23
|
)
|
||
Total debt
|
2,939
|
|
|
2,819
|
|
||
Short-term debt (includes current portion of long-term debt)
|
(355
|
)
|
|
(235
|
)
|
||
Long-term debt (less current portion and debt issuance cost discounts)
|
$
|
2,584
|
|
|
$
|
2,584
|
|
|
|
|
|
(a)
|
Other includes
$24 million
and
$25 million
of debt issuance cost discounts as of
December 31, 2017
and
September 30, 2017
, respectively.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In millions)
|
|
|
|
Balance at October 1, 2017
|
$
|
194
|
|
Increases related to positions taken on items from prior years
|
2
|
|
|
Increases related to positions taken in the current year
|
3
|
|
|
Balance at December 31, 2017
|
$
|
199
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other postretirement
|
||||||||||
|
Pension benefits
|
|
benefits
|
||||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
||||
Three months ended December 31
|
|
|
|
|
|
|
|
||||||||
Service cost
(a)
|
$
|
2
|
|
|
$
|
2
|
|
|
$
|
1
|
|
|
$
|
—
|
|
Interest cost
(b)
|
3
|
|
|
2
|
|
|
—
|
|
|
1
|
|
||||
Expected return on plan assets
(b)
|
(3
|
)
|
|
(3
|
)
|
|
—
|
|
|
—
|
|
||||
Actuarial gain
(b)
|
—
|
|
|
—
|
|
|
—
|
|
|
(2
|
)
|
||||
Total net periodic benefit costs (income)
|
$
|
2
|
|
|
$
|
1
|
|
|
$
|
1
|
|
|
$
|
(1
|
)
|
|
|
|
|
|
|
|
|
(a)
|
Service cost was not impacted by new accounting guidance adopted in the current quarter and is therefore still classified within the selling, general and administrative expense and cost of sales captions on the Statements of Consolidated Comprehensive Income (Loss). See Note A for additional information.
|
(b)
|
These components are now classified within the other net periodic benefit income caption on the Statements of Consolidated Comprehensive Income (Loss) due to the adoption of new accounting guidance in the current quarter. See Note A for additional information.
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
|
|
|
|
|
|||||||
|
December 31
|
|
Years ended September 30
|
|||||||||||
(In thousands)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
2015
|
|
Open claims - beginning of period
|
54
|
|
|
57
|
|
|
57
|
|
|
60
|
|
|
65
|
|
New claims filed
|
1
|
|
|
—
|
|
|
2
|
|
|
2
|
|
|
2
|
|
Claims settled
|
—
|
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
Claims dismissed
|
(1
|
)
|
|
(1
|
)
|
|
(4
|
)
|
|
(5
|
)
|
|
(7
|
)
|
Open claims - end of period
|
54
|
|
|
56
|
|
|
54
|
|
|
57
|
|
|
60
|
|
|
Three months ended
|
|
|
|
|
|
|
||||||||||||
|
December 31
|
|
Years ended September 30
|
||||||||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
2015
|
|
|||||
Asbestos reserve - beginning of period
|
$
|
419
|
|
|
$
|
415
|
|
|
$
|
415
|
|
|
$
|
409
|
|
|
$
|
438
|
|
Reserve adjustment
|
—
|
|
|
—
|
|
|
36
|
|
|
37
|
|
|
—
|
|
|||||
Amounts paid
|
(10
|
)
|
|
(9
|
)
|
|
(32
|
)
|
|
(31
|
)
|
|
(29
|
)
|
|||||
Asbestos reserve - end of period
(a)
|
$
|
409
|
|
|
$
|
406
|
|
|
$
|
419
|
|
|
$
|
415
|
|
|
$
|
409
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
Included
$34 million
classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of
December 31, 2017
and
September 30, 2017
.
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
|
|
|
|
|
||||||||||||
|
December 31
|
|
Years ended September 30
|
||||||||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
2015
|
|
|||||
Insurance receivable - beginning of period
|
$
|
155
|
|
|
$
|
151
|
|
|
$
|
151
|
|
|
$
|
150
|
|
|
$
|
402
|
|
Receivable adjustment
|
—
|
|
|
—
|
|
|
15
|
|
|
16
|
|
|
(3
|
)
|
|||||
Insurance settlement
|
—
|
|
|
—
|
|
|
(5
|
)
|
|
(4
|
)
|
|
(227
|
)
|
|||||
Amounts collected
|
(4
|
)
|
|
(2
|
)
|
|
(6
|
)
|
|
(11
|
)
|
|
(22
|
)
|
|||||
Insurance receivable - end of period
(a)
|
$
|
151
|
|
|
$
|
149
|
|
|
$
|
155
|
|
|
$
|
151
|
|
|
$
|
150
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
Included
$14 million
classified in accounts receivable on the Condensed Consolidated Balance Sheets as of
December 31, 2017
and
September 30, 2017
.
|
|
Three months ended
|
|
|
|
|
|
|
|||||||
|
December 31
|
|
Years ended September 30
|
|||||||||||
(In thousands)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
2015
|
|
Open claims - beginning of period
|
12
|
|
|
15
|
|
|
15
|
|
|
20
|
|
|
21
|
|
New claims filed
|
—
|
|
|
—
|
|
|
1
|
|
|
1
|
|
|
1
|
|
Claims dismissed
|
—
|
|
|
—
|
|
|
(4
|
)
|
|
(6
|
)
|
|
(2
|
)
|
Open claims - end of period
|
12
|
|
|
15
|
|
|
12
|
|
|
15
|
|
|
20
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
|
|
|
|
|
||||||||||||
|
December 31
|
|
Years ended September 30
|
||||||||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
2015
|
|
|||||
Asbestos reserve - beginning of period
|
$
|
323
|
|
|
$
|
321
|
|
|
$
|
321
|
|
|
$
|
311
|
|
|
$
|
329
|
|
Reserve adjustment
|
—
|
|
|
—
|
|
|
16
|
|
|
25
|
|
|
4
|
|
|||||
Amounts paid
|
(8
|
)
|
|
(3
|
)
|
|
(14
|
)
|
|
(15
|
)
|
|
(22
|
)
|
|||||
Asbestos reserve - end of period (a)
|
$
|
315
|
|
|
$
|
318
|
|
|
$
|
323
|
|
|
$
|
321
|
|
|
$
|
311
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
Included
$14 million
classified in accrued expenses and other liabilities on the Condensed Consolidated Balance Sheets as of
December 31, 2017
and
September 30, 2017
.
|
|
Three months ended
|
|
|
|
|
|
|
||||||||||||
|
December 31
|
|
Years ended September 30
|
||||||||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
2015
|
|
|||||
Insurance receivable - beginning of period
|
$
|
68
|
|
|
$
|
63
|
|
|
$
|
63
|
|
|
$
|
56
|
|
|
$
|
77
|
|
Receivable adjustment
|
—
|
|
|
—
|
|
|
5
|
|
|
7
|
|
|
1
|
|
|||||
Insurance settlement
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(22
|
)
|
|||||
Insurance receivable - end of period
|
$
|
68
|
|
|
$
|
63
|
|
|
$
|
68
|
|
|
$
|
63
|
|
|
$
|
56
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Reserve - beginning of period
|
$
|
163
|
|
|
$
|
177
|
|
Disbursements
|
(8
|
)
|
|
(7
|
)
|
||
Revised obligation estimates and accretion
|
13
|
|
|
4
|
|
||
Reserve - end of period
|
$
|
168
|
|
|
$
|
174
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Environmental expense
|
$
|
12
|
|
|
$
|
4
|
|
Accretion
|
1
|
|
|
—
|
|
||
Legal expense
|
1
|
|
|
2
|
|
||
Total expense
|
14
|
|
|
6
|
|
||
|
|
|
|
||||
Insurance receivable
(a)
|
—
|
|
|
—
|
|
||
Total expense, net of receivable activity
|
$
|
14
|
|
|
$
|
6
|
|
|
|
|
|
(a)
|
Activity of $0 denotes value less than $1 million.
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions except per share data)
|
2017
|
|
|
2016
|
|
||
Numerator
|
|
|
|
||||
Numerator for basic and diluted EPS –
|
|
|
|
||||
Loss from continuing operations
|
$
|
(7
|
)
|
|
$
|
(65
|
)
|
Denominator
|
|
|
|
|
|
||
Denominator for basic EPS – Weighted-average
|
|
|
|
|
|
||
common shares outstanding
|
62
|
|
|
62
|
|
||
Share-based awards convertible to common shares
(a)
|
—
|
|
|
—
|
|
||
Denominator for diluted EPS – Adjusted weighted-
|
|
|
|
|
|
||
average shares and assumed conversions
|
62
|
|
|
62
|
|
||
|
|
|
|
||||
EPS from continuing operations attributable to Ashland
|
|
|
|
||||
Basic
|
$
|
(0.12
|
)
|
|
$
|
(1.05
|
)
|
Diluted
|
(0.12
|
)
|
|
(1.05
|
)
|
||
|
|
|
|
(a)
|
As a result of the loss from continuing operations attributable to Ashland during the three months ended
December 31, 2017
and 2016, the effect of the share-based awards convertible to common shares would be antidilutive. In accordance with U.S. GAAP, they have been excluded from the diluted EPS calculation.
|
|
|
|
|
|
|
|
|
|
|
2017
|
|
2016
|
||||||||||||||||||||
|
|
|
Tax
|
|
|
|
|
|
|
Tax
|
|
|
|
||||||||||
|
Before
|
|
|
(expense)
|
|
|
Net of
|
|
|
Before
|
|
|
(expense)
|
|
|
Net of
|
|
||||||
(In millions)
|
tax
|
|
|
benefit
|
|
|
tax
|
|
|
tax
|
|
|
benefit
|
|
|
tax
|
|
||||||
Three months ended December 31
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Other comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Unrealized translation gain (loss)
|
$
|
3
|
|
|
$
|
—
|
|
|
$
|
3
|
|
|
$
|
(150
|
)
|
|
$
|
4
|
|
|
$
|
(146
|
)
|
Pension and postretirement obligation adjustment:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Amortization of unrecognized prior service
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
credits included in net income
(a)
|
—
|
|
|
—
|
|
|
—
|
|
|
(3
|
)
|
|
2
|
|
|
(1
|
)
|
||||||
Net change in available-for-sale securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Unrealized gains during period
|
11
|
|
|
(2
|
)
|
|
9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Reclassification adjustment for realized gains
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
included in net income
|
(1
|
)
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
Total other comprehensive income (loss)
|
$
|
13
|
|
|
$
|
(2
|
)
|
|
$
|
11
|
|
|
$
|
(153
|
)
|
|
$
|
6
|
|
|
$
|
(147
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
For the three months ended December 31, 2016, the amortization of unrecognized prior service credits was related to pension and other postretirement benefit plans that transferred to Valvoline and was classified in the discontinued operations caption on the Statements of Consolidated Comprehensive Income (Loss).
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
(a)
|
|
|
2016
(b)
|
|
||
SARs
|
$
|
1
|
|
|
$
|
1
|
|
Nonvested stock awards
|
6
|
|
|
4
|
|
||
Performance awards
|
4
|
|
|
2
|
|
||
|
$
|
11
|
|
|
$
|
7
|
|
|
|
|
|
(a)
|
The three months ended
December 31, 2017
included
$2 million
of expense related to cash-settled nonvested restricted stock awards and
$2 million
of expense related to cash-settled performance units.
|
(b)
|
The three months ended
December 31, 2016
included
$1 million
of expense related to cash-settled nonvested restricted stock awards and
$1 million
of expense related to cash-settled performance units.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions - unaudited)
|
2017
|
|
|
2016
|
|
||
SALES
|
|
|
|
||||
Specialty Ingredients
|
$
|
550
|
|
|
$
|
482
|
|
Composites
|
218
|
|
|
165
|
|
||
Intermediates and Solvents
|
74
|
|
|
57
|
|
||
|
$
|
842
|
|
|
$
|
704
|
|
OPERATING INCOME (LOSS)
|
|
|
|
|
|
||
Specialty Ingredients
|
$
|
42
|
|
|
$
|
40
|
|
Composites
|
18
|
|
|
15
|
|
||
Intermediates and Solvents
|
8
|
|
|
(7
|
)
|
||
Unallocated and other
|
(29
|
)
|
|
(33
|
)
|
||
|
$
|
39
|
|
|
$
|
15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||
|
December 31
|
||||
Sales by Geography
|
2017
|
|
|
2016
|
|
North America
(a)
|
40
|
%
|
|
40
|
%
|
Europe
|
34
|
%
|
|
31
|
%
|
Asia Pacific
|
18
|
%
|
|
20
|
%
|
Latin America & other
|
8
|
%
|
|
9
|
%
|
|
100
|
%
|
|
100
|
%
|
|
|
|
|
|
Three months ended
|
||||
|
December 31
|
||||
Sales by Reportable Segment
|
2017
|
|
|
2016
|
|
Specialty Ingredients
|
65
|
%
|
|
69
|
%
|
Composites
|
26
|
%
|
|
23
|
%
|
Intermediates and Solvents
|
9
|
%
|
|
8
|
%
|
|
100
|
%
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
•
|
EBITDA - net income (loss), plus income tax expense (benefit), net interest and other financing expenses, and depreciation and amortization.
|
•
|
Adjusted EBITDA - EBITDA adjusted for noncontrolling interests, discontinued operations, net gain (loss) on acquisitions and divestitures, other income and (expense) and key items (including the remeasurement gains and losses related to pension and other postretirement plans).
|
•
|
Adjusted EBITDA margin - Adjusted EBITDA, which can include pro forma adjustments, divided by sales.
|
•
|
Adjusted diluted earnings per share (EPS) - income (loss) from continuing operations, adjusted for key items, net of tax, divided by the average outstanding diluted shares for the applicable period.
|
•
|
Free cash flow - operating cash flows less capital expenditures and certain other adjustments as applicable.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
Ashland’s net loss attributable to Ashland amounted to
$4 million
and
$1 million
for the three months ended
December 31, 2017
and
2016
, respectively, or a loss of
$0.07
and
$0.01
diluted earnings per share, respectively.
|
•
|
Ashland’s net income attributable to noncontrolling interest amounted to
$11 million
for the three months ended
December 31, 2016
and reflects the noncontrolling interest of Valvoline Inc. before the final separation occurred on May 12, 2017.
|
•
|
Discontinued operations, which are reported net of taxes, resulted in income of
$3 million
and
$75 million
during the three months ended
December 31, 2017
and
2016
, respectively. The activity within discontinued operations for the three months ended
December 31, 2016
includes the operating results of Valvoline Inc.
|
•
|
Loss from continuing operations, which excludes results from discontinued operations, amounted to
$7 million
and
$65 million
for the three months ended
December 31, 2017
and
2016
, respectively.
|
•
|
The effective income tax rate was
200%
and
39%
for the three months ended
December 31, 2017
and
2016
, and was impacted by certain discrete items in both the current and prior year quarters. The current quarter rate was primarily impacted by income mix and net unfavorable tax discrete adjustments of $16 million related to the Tax Act.
|
•
|
Ashland incurred pretax net interest and other financing expense of
$31 million
and
$122 million
for the three months ended
December 31, 2017
and
2016
, respectively. The prior year quarter was impacted by $92 million of net charges associated with debt financing activity.
|
•
|
Operating income was
$39 million
and
$15 million
for the three months ended
December 31, 2017
and
2016
, respectively.
|
|
|
|
|
|
|
|
|
|
◦
|
$6 million
and
$22 million
of costs related to the separation of Valvoline during the three months ended
December 31, 2017
and
2016
, respectively;
|
◦
|
$4 million of accelerated depreciation related to the planned closure of an office building during the three months ended
December 31, 2017
;
|
◦
|
$2 million of accelerated depreciation for the termination of a contract at a manufacturing facility during the three months ended
December 31, 2017
;
|
◦
|
$1 million of severance and other restructuring charges for the closure of a manufacturing plant during the three months ended
December 31, 2017
; and
|
◦
|
$1 million of integration costs related to the acquisition of Pharmachem for the three months ended
December 31, 2017
;
|
•
|
Remeasurement gain of $2 million associated with the discontinuation of certain post-employment health and life insurance benefits during the three months ended
December 31, 2016
; and
|
•
|
a $5 million charge for a legal reserve during the three months ended
December 31, 2016
.
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Net income (loss)
|
$
|
(4
|
)
|
|
$
|
10
|
|
Income tax expense (benefit)
|
14
|
|
|
(41
|
)
|
||
Net interest and other financing expense
|
31
|
|
|
122
|
|
||
Depreciation and amortization
(a)
|
73
|
|
|
68
|
|
||
EBITDA
|
114
|
|
|
159
|
|
||
Income from discontinued operations (net of tax)
|
(3
|
)
|
|
(75
|
)
|
||
Environmental reserve adjustments
|
11
|
|
|
—
|
|
||
Separation, restructuring and other costs
|
8
|
|
|
22
|
|
||
Accelerated depreciation
|
6
|
|
|
—
|
|
||
Legal reserve
|
—
|
|
|
5
|
|
||
Gain on post-employment plan remeasurement
|
—
|
|
|
(2
|
)
|
||
Adjusted EBITDA
(b)
|
$
|
136
|
|
|
$
|
109
|
|
|
|
|
|
(a)
|
Excludes
$6 million
of accelerated depreciation for the
three
months ended
December 31, 2017
.
|
|
Three months ended
|
||||||
|
December 31
|
||||||
|
2017
|
|
|
2016
|
|
||
Diluted EPS from continuing operations (as reported)
|
$
|
(0.12
|
)
|
|
$
|
(1.05
|
)
|
Key items
|
0.54
|
|
|
1.19
|
|
||
Adjusted diluted EPS from continuing operations (non-GAAP)
|
$
|
0.42
|
|
|
$
|
0.14
|
|
|
Three months ended December 31
|
|
||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|
|||
Sales
|
$
|
842
|
|
|
$
|
704
|
|
|
$
|
138
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
|
||
(In millions)
|
December 31, 2017
|
|
||
Acquisitions and divestitures
|
|
$
|
63
|
|
Pricing
|
|
30
|
|
|
Currency exchange
|
|
20
|
|
|
Volume
|
|
18
|
|
|
Product mix
|
|
7
|
|
|
Change in sales
|
|
$
|
138
|
|
|
Three months ended December 31
|
||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|||
Cost of sales
|
$
|
613
|
|
|
$
|
515
|
|
|
$
|
98
|
|
Gross profit as a percent of sales
|
27.2
|
%
|
|
26.8
|
%
|
|
|
|
|
Three months ended
|
|
||
(In millions)
|
December 31, 2017
|
|
||
Changes in:
|
|
|
||
Acquisitions and divestitures
|
|
$
|
50
|
|
Production costs
|
|
20
|
|
|
Currency exchange
|
|
15
|
|
|
Volume
|
|
8
|
|
|
Product mix
|
|
4
|
|
|
Severance and other restructuring costs
|
|
1
|
|
|
Change in cost of sales
|
|
$
|
98
|
|
|
Three months ended December 31
|
||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|||
Selling, general and administrative expense
|
$
|
171
|
|
|
$
|
157
|
|
|
$
|
14
|
|
As a percent of sales
|
20.3
|
%
|
|
22.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
$10 million of incremental costs related to Pharmachem’s operations and $1 million of Pharmachem integration costs during the current quarter;
|
•
|
$14 million
and
$6 million
in net environmental-related expenses during the current and prior year quarters, respectively;
|
•
|
an increase of $7 million due to higher employee-related costs in the current quarter;
|
•
|
an increase of $5 million due to unfavorable foreign currency exchange in the current quarter;
|
•
|
$4 million of accelerated depreciation related to the planned closure of an office building during the current quarter;
|
•
|
$6 million
of costs related to the separation of Valvoline during the current quarter compared to
$22 million
in the prior year quarter; and
|
•
|
a $5 million charge for a legal reserve during the prior year quarter.
|
|
Three months ended December 31
|
||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|||
Research and development expense
|
$
|
21
|
|
|
$
|
20
|
|
|
$
|
1
|
|
|
Three months ended December 31
|
||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|||
Equity and other income
|
|
|
|
|
|
|
|
|
|||
Equity income
(a)
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Other income
|
2
|
|
|
3
|
|
|
(1
|
)
|
|||
|
$
|
2
|
|
|
$
|
3
|
|
|
$
|
(1
|
)
|
|
|
|
|
|
|
(a)
|
Activity of $0 denotes value less than $1 million.
|
|
Three months ended December 31
|
||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|||
Net interest and other financing expense (income)
|
|
|
|
|
|
||||||
Interest expense
|
$
|
34
|
|
|
$
|
126
|
|
|
$
|
(92
|
)
|
Interest income
|
(1
|
)
|
|
(1
|
)
|
|
—
|
|
|||
Available-for-sale securities income
|
(3
|
)
|
|
(3
|
)
|
|
—
|
|
|||
Other financing costs
|
1
|
|
|
—
|
|
|
1
|
|
|||
|
$
|
31
|
|
|
$
|
122
|
|
|
$
|
(91
|
)
|
|
|
|
|
|
|
|
|
|
|
Three months ended December 31
|
||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|||
Other net periodic benefit income
|
$
|
—
|
|
|
$
|
2
|
|
|
$
|
(2
|
)
|
|
Three months ended December 31
|
||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|||
Net loss on divestitures
|
$
|
1
|
|
|
$
|
1
|
|
|
$
|
—
|
|
|
Three months ended December 31
|
||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|||
Income tax expense (benefit)
|
$
|
14
|
|
|
$
|
(41
|
)
|
|
$
|
55
|
|
Effective tax rate
|
200
|
%
|
|
39
|
%
|
|
|
|
|
Three months ended December 31
|
||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|||
Income from discontinued operations (net of tax)
|
|
|
|
|
|
||||||
Valvoline
|
$
|
3
|
|
|
$
|
75
|
|
|
$
|
(72
|
)
|
|
Three months ended December 31
|
||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|||
Net income attributable to noncontrolling interest
|
$
|
—
|
|
|
$
|
11
|
|
|
$
|
(11
|
)
|
|
|
|
|
|
|
|
|
|
|
Three months ended December 31
|
||||||||||
(In millions)
|
2017
|
|
|
2016
|
|
|
Change
|
|
|||
Other comprehensive income (loss) (net of taxes)
|
|
|
|
|
|
||||||
Unrealized translation gain (loss)
|
$
|
3
|
|
|
$
|
(146
|
)
|
|
$
|
149
|
|
Net change in available-for-sale securities
|
8
|
|
|
—
|
|
|
8
|
|
|||
Pension and postretirement obligation adjustment
|
—
|
|
|
(1
|
)
|
|
1
|
|
|||
|
$
|
11
|
|
|
$
|
(147
|
)
|
|
$
|
158
|
|
•
|
For the three months ended
December 31, 2017
, the change in unrealized gain (loss) from foreign currency translation adjustments was a gain of
$3 million
compared to a loss of
$146 million
for the three months ended
December 31, 2016
. The fluctuations in unrealized translation gains and losses are primarily due to translating foreign subsidiary financial statements from local currencies to U.S. Dollars.
|
•
|
Gains on available-for-sale securities related to restricted investments amounted to
$8 million
, net of tax, during the three months ended
December 31, 2017
.
|
•
|
Pension and postretirement obligation adjustment was
$1 million
for the three months ended
December 31, 2016
. This amount related to amortization of unrecognized prior services credits for pension and other postretirement benefit plans and was reclassified into net income during the prior year quarter.
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Sales
|
|
|
|
||||
Specialty Ingredients
|
$
|
550
|
|
|
$
|
482
|
|
Composites
|
218
|
|
|
165
|
|
||
Intermediates and Solvents
|
74
|
|
|
57
|
|
||
|
$
|
842
|
|
|
$
|
704
|
|
Operating income (loss)
|
|
|
|
|
|
||
Specialty Ingredients
|
$
|
42
|
|
|
$
|
40
|
|
Composites
|
18
|
|
|
15
|
|
||
Intermediates and Solvents
|
8
|
|
|
(7
|
)
|
||
Unallocated and other
|
(29
|
)
|
|
(33
|
)
|
||
|
$
|
39
|
|
|
$
|
15
|
|
Depreciation and amortization
|
|
|
|
|
|
||
Specialty Ingredients
|
$
|
62
|
|
|
$
|
55
|
|
Composites
|
5
|
|
|
6
|
|
||
Intermediates and Solvents
|
8
|
|
|
7
|
|
||
Unallocated and other
|
4
|
|
|
—
|
|
||
|
$
|
79
|
|
|
$
|
68
|
|
Operating information
|
|
|
|
|
|
||
Specialty Ingredients
|
|
|
|
|
|
||
Sales per shipping day
|
$
|
9.0
|
|
|
$
|
7.9
|
|
Metric tons sold (thousands)
|
73.0
|
|
|
72.6
|
|
||
Gross profit as a percent of sales
(a)
|
31.5
|
%
|
|
32.0
|
%
|
||
Composites
|
|
|
|
|
|||
Sales per shipping day
|
$
|
3.6
|
|
|
$
|
2.7
|
|
Metric tons sold (thousands)
|
91.2
|
|
|
78.4
|
|
||
Gross profit as a percent of sales
(a)
|
18.4
|
%
|
|
21.1
|
%
|
||
Intermediates and Solvents
|
|
|
|
|
|
||
Sales per shipping day
|
$
|
1.2
|
|
|
$
|
0.9
|
|
Metric tons sold (thousands)
|
32.7
|
|
|
32.2
|
|
||
Gross profit as a percent of sales
(a)
|
21.3
|
%
|
|
(0.9
|
)%
|
||
|
|
|
|
(a)
|
Gross profit is defined as sales, less cost of sales divided by sales.
|
|
|
|
|
|
|
|
|
|
|
Three months ended December 31, 2017
|
|||||||
Sales by Geography
|
Specialty Ingredients
|
|
Composites
|
|
Intermediates and Solvents
|
|||
North America
|
41
|
%
|
|
45
|
%
|
|
21
|
%
|
Europe
|
30
|
%
|
|
34
|
%
|
|
59
|
%
|
Asia Pacific
|
19
|
%
|
|
14
|
%
|
|
17
|
%
|
Latin America & other
|
10
|
%
|
|
7
|
%
|
|
3
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
Three months ended December 31, 2016
|
|||||||
Sales by Geography
|
Specialty Ingredients
|
|
Composites
|
|
Intermediates and Solvents
|
|||
North America
|
39
|
%
|
|
48
|
%
|
|
23
|
%
|
Europe
|
29
|
%
|
|
28
|
%
|
|
57
|
%
|
Asia Pacific
|
22
|
%
|
|
16
|
%
|
|
17
|
%
|
Latin America & other
|
10
|
%
|
|
8
|
%
|
|
3
|
%
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Operating income
|
$
|
42
|
|
|
$
|
40
|
|
Depreciation and amortization
(a)
|
60
|
|
|
55
|
|
||
EBITDA
|
102
|
|
|
95
|
|
||
Accelerated depreciation
|
2
|
|
|
—
|
|
||
Severance and other restructuring costs
|
1
|
|
|
—
|
|
||
Adjusted EBITDA
|
$
|
105
|
|
|
$
|
95
|
|
|
|
|
|
(a)
|
Excludes
$2 million
of accelerated depreciation for the three months ended December 31, 2017.
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Operating income
|
$
|
18
|
|
|
$
|
15
|
|
Depreciation and amortization
|
5
|
|
|
6
|
|
||
EBITDA
|
$
|
23
|
|
|
$
|
21
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Operating income (loss)
|
$
|
8
|
|
|
$
|
(7
|
)
|
Depreciation and amortization
|
8
|
|
|
7
|
|
||
EBITDA
|
$
|
16
|
|
|
$
|
—
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Restructuring activities (includes separation, severance, integration
|
|
|
|
||||
and stranded divestiture costs)
|
$
|
14
|
|
|
$
|
24
|
|
Environmental expense for divested businesses
|
13
|
|
|
4
|
|
||
Legal reserve
|
—
|
|
|
5
|
|
||
Other expense
|
2
|
|
|
—
|
|
||
Total expense
|
$
|
29
|
|
|
$
|
33
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Cash provided (used) by:
|
|
|
|
||||
Operating activities from continuing operations
|
$
|
(24
|
)
|
|
$
|
(60
|
)
|
Investing activities from continuing operations
|
(24
|
)
|
|
(31
|
)
|
||
Financing activities from continuing operations
|
99
|
|
|
(434
|
)
|
||
Discontinued operations
|
(16
|
)
|
|
50
|
|
||
Effect of currency exchange rate changes on cash and cash equivalents
|
—
|
|
|
(9
|
)
|
||
Net increase (decrease) in cash and cash equivalents
|
$
|
35
|
|
|
$
|
(484
|
)
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Cash flows provided (used) by operating activities from continuing operations
|
|
|
|
||||
Net income (loss)
|
$
|
(4
|
)
|
|
$
|
10
|
|
Income from discontinued operations (net of tax)
|
(3
|
)
|
|
(75
|
)
|
||
Adjustments to reconcile income from continuing operations to
|
|
|
|
|
|
||
cash flows from operating activities
|
|
|
|
|
|
||
Depreciation and amortization
|
79
|
|
|
68
|
|
||
Original issue discount and debt issuance cost amortization
|
2
|
|
|
94
|
|
||
Deferred income taxes
|
8
|
|
|
2
|
|
||
Stock based compensation expense
|
7
|
|
|
5
|
|
||
Gain on early retirement of debt
|
—
|
|
|
(3
|
)
|
||
Realized gain and investment income on available-for-sale securities
|
(3
|
)
|
|
(3
|
)
|
||
Net loss on divestitures
|
1
|
|
|
1
|
|
||
Pension contributions
|
(2
|
)
|
|
(1
|
)
|
||
Gain on post-employment plan remeasurement
|
—
|
|
|
(2
|
)
|
||
Change in operating assets and liabilities
(a)
|
(109
|
)
|
|
(156
|
)
|
||
Total cash flows used by operating activities from continuing operations
|
$
|
(24
|
)
|
|
$
|
(60
|
)
|
|
|
|
|
•
|
Accounts receivable - There were cash inflows of $15 million and $9 million during the current and prior year quarters, respectively, which were primarily due to collections in excess of sales during the first quarter of each fiscal year.
|
•
|
Inventory - The current quarter had a cash outflow of $39 million compared to a cash inflow of $15 million during the prior year quarter, which were primarily due to sales volumes and inventory management strategies.
|
•
|
Trade and other payables - There were cash outflows of $72 million and $95 million during the current and prior year quarters, respectively, which were primarily driven by seasonal fluctuations in trade payables and incentive compensation payouts from the prior year paid during the first quarter of each fiscal year. Additionally, the prior year quarter included the payment of certain Valvoline separation costs that were incurred in the preceding fiscal year.
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Cash flows provided (used) by investing activities from continuing operations
|
|
|
|
||||
Additions to property, plant and equipment
|
$
|
(24
|
)
|
|
$
|
(33
|
)
|
Proceeds from disposal of property, plant and equipment
|
1
|
|
|
—
|
|
||
Proceeds from sale of operations
|
1
|
|
|
—
|
|
||
Net purchase of funds restricted for specific transactions
|
(5
|
)
|
|
(2
|
)
|
||
Reimbursements from restricted investments
|
5
|
|
|
—
|
|
||
Proceeds from sales of available-for-sale securities
|
5
|
|
|
—
|
|
||
Purchases of available-for-sale securities
|
(5
|
)
|
|
—
|
|
||
Proceeds from the settlement of derivative instruments
|
—
|
|
|
4
|
|
||
Payments for the settlement of derivative instruments
|
(2
|
)
|
|
—
|
|
||
Total cash flows used by investing activities from continuing operations
|
$
|
(24
|
)
|
|
$
|
(31
|
)
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Cash flows provided (used) by financing activities from continuing operations
|
|
|
|
||||
Repayment of long-term debt
|
$
|
(2
|
)
|
|
$
|
(239
|
)
|
Premium on long-term debt repayment
|
—
|
|
|
(5
|
)
|
||
Proceeds (repayment) from short-term debt
|
120
|
|
|
(154
|
)
|
||
Debt issuance costs
|
—
|
|
|
(4
|
)
|
||
Cash dividends paid
|
(14
|
)
|
|
(24
|
)
|
||
Stock based compensation employee withholding taxes paid in cash
|
(5
|
)
|
|
(8
|
)
|
||
Total cash flows provided (used) by financing activities from continuing operations
|
$
|
99
|
|
|
$
|
(434
|
)
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Cash used by discontinued operations
|
|
|
|
||||
Operating cash flows
|
$
|
(16
|
)
|
|
$
|
70
|
|
Investing cash flows
|
—
|
|
|
(10
|
)
|
||
Financing cash flows
|
—
|
|
|
(10
|
)
|
||
Total cash provided (used) by discontinued operations
|
$
|
(16
|
)
|
|
$
|
50
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
|
||||||
|
December 31
|
||||||
(In millions)
|
2017
|
|
|
2016
|
|
||
Cash flows provided by operating activities from continuing operations
|
$
|
(24
|
)
|
|
$
|
(60
|
)
|
Adjustments:
|
|
|
|
|
|
||
Additions to property, plant and equipment
|
(24
|
)
|
|
(33
|
)
|
||
Free cash flows
(a)
|
$
|
(48
|
)
|
|
$
|
(93
|
)
|
|
|
|
|
(a)
|
Includes $23 million and $29 million of restructuring payments for the three months ended December 31, 2017 and 2016, respectively.
|
|
December 31
|
|
|
September 30
|
|
||
(In millions)
|
2017
|
|
|
2017
|
|
||
Cash and cash equivalents
|
$
|
601
|
|
|
$
|
566
|
|
|
|
|
|
||||
Unused borrowing capacity
|
|
|
|
|
|
||
2017 Revolving Credit Facility
|
$
|
467
|
|
|
$
|
579
|
|
Accounts receivable securitization facility
|
31
|
|
|
35
|
|
|
December 31
|
|
|
September 30
|
|
||
(In millions)
|
2017
|
|
|
2017
|
|
||
Short-term debt (includes current portion of long-term debt)
|
$
|
355
|
|
|
$
|
235
|
|
Long-term debt (including current portion and debt issuance cost discounts)
(a)
|
2,584
|
|
|
2,584
|
|
||
Total debt
|
$
|
2,939
|
|
|
$
|
2,819
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Prior FY 2018 Outlook
|
Updated FY 2018 Outlook
|
Adjusted EBITDA
|
|
|
Specialty Ingredients
|
$560 - $590 million
|
No change
|
Composites
|
$85 - $95 million
|
No change
|
Intermediates & Solvents
|
$40 - $50 million
|
No change
|
Unallocated and other
|
($35 - $45 million)
|
No change
|
|
|
|
Key Operating Metrics
|
|
|
Free cash flow
|
>$220 million
|
No change
|
Adjusted diluted EPS
|
$3.20 - $3.40
|
$2.90 - $3.10
|
|
|
|
Corporate Items
|
|
|
Depreciation & amortization
|
~$290 million
|
No change
|
Interest expense
|
$125 - $135 million
|
No change
|
Effective tax rate
|
8 - 13%
|
16 - 20%
|
Capital expenditures
|
$195 - $205 million
|
No change
|
Diluted share count
|
~64 million
|
No change
|
|
|
|
|
|
|
|
|
|
Issuer Purchases of Equity Securities
|
||||||||||||||
Q1 Fiscal Periods
|
Total Number of Shares Purchased
|
Average Price Paid Per Share, including commission
|
|
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
|
|
Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (in millions)(a)
|
||||||||
October 1, 2017 to October 31, 2017
|
—
|
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
500
|
|
November 1, 2017 to November 30, 2017:
|
|
|
|
|
|
|
|
|
|
|||||
Employee Tax Withholdings
|
16,465
|
|
(b)
|
|
66.56
|
|
|
—
|
|
|
500
|
|
||
December 1, 2017 to December 31, 2017
|
—
|
|
|
|
—
|
|
|
—
|
|
|
500
|
|
||
Total..........................................................
|
16,465
|
|
|
|
|
|
—
|
|
|
$
|
500
|
|
(a) Exhibits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.INS**
|
XBRL Instance Document.
|
|
|
101.SCH**
|
XBRL Taxonomy Extension Schema Document.
|
|
|
101.CAL**
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
|
101.DEF**
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
|
|
101.LAB**
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
|
101.PRE**
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
Ashland Global Holdings Inc.
|
|
(Registrant)
|
January 30, 2018
|
/s/ J. Kevin Willis
|
|
J. Kevin Willis
|
|
Senior Vice President and Chief Financial Officer
(on behalf of the Registrant and as principal
financial officer)
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
No Customers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|